Rift valley fever future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Aakash Hans (talk | contribs) No edit summary |
Aakash Hans (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Rift valley fever}} | {{Rift valley fever}} | ||
{{CMG}}{{AE}} {{AAH}} | |||
*Many [[Vaccine|vaccines]] are under investigational testing for use in livestock.<ref>Njenga MK, Njagi L, Thumbi SM, et al. Randomized controlled field trial to assess the immunogenicity and safety of rift valley fever clone 13 vaccine in livestock. PLoS neglected tropical diseases. 2015 Mar;9(3):e0003550.</ref> | *Many [[Vaccine|vaccines]] are under investigational testing for use in livestock.<ref>Njenga MK, Njagi L, Thumbi SM, et al. Randomized controlled field trial to assess the immunogenicity and safety of rift valley fever clone 13 vaccine in livestock. PLoS neglected tropical diseases. 2015 Mar;9(3):e0003550.</ref> | ||
*Some vaccines being developed may be safe to use in both animals and humans. | *Some vaccines being developed may be safe to use in both animals and humans. | ||
Revision as of 17:47, 16 July 2021
|
Rift valley fever Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Rift valley fever future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Rift valley fever future or investigational therapies |
|
FDA on Rift valley fever future or investigational therapies |
|
CDC on Rift valley fever future or investigational therapies |
|
Rift valley fever future or investigational therapies in the news |
|
Blogs on Rift valley fever future or investigational therapies |
|
Risk calculators and risk factors for Rift valley fever future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Aakash Hans, MD[2]
- Many vaccines are under investigational testing for use in livestock.[1]
- Some vaccines being developed may be safe to use in both animals and humans.
- Ribavirin showed promise in rodent models but was stopped after development of neurological symptoms in some of the patients it was administered during the RVF outbreak in Saudi Arabia in the year 2000. [2]
- Significant financial investment would be required to undergo vaccine development on a large scale.
References
- ↑ Njenga MK, Njagi L, Thumbi SM, et al. Randomized controlled field trial to assess the immunogenicity and safety of rift valley fever clone 13 vaccine in livestock. PLoS neglected tropical diseases. 2015 Mar;9(3):e0003550.
- ↑ Bird BH, Reynes JM, Nichol ST. Rift Valley Fever. In: Magill AJ, Strickland GT, Maguire JH, Ryan ET, Solomon T, editors. Hunter’s Tropical Medicine and Emerging Infectious Disease. 9. Elsevier Health Sciences; 2012.